Determine the necessary mass, volume, or concentration for preparing a solution.
This is a demo store. No orders will be fulfilled.
| SKU | Size | Availability |
Price | Qty |
|---|---|---|---|---|
|
B411998-100μg
|
100μg |
4
|
$69.90
|
|
|
B411998-1mg
|
1mg |
Available within 4-8 weeks(?)
Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience!
|
$349.90
|
|
|
B411998-5mg
|
5mg |
Available within 4-8 weeks(?)
Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience!
|
$1,559.90
|
|
|
B411998-10mg
|
10mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$2,339.90
|
|
Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
| Product Name | Bevacizumab (anti-VEGF) - Primary antibody, for ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) various applications, specific to VEGFA, >95%, high purity, Human IgG1, INHIBITOR of Vascular endothelial growth factor A inhibitor |
|---|---|
| Synonyms | Recombinant Bevacizumab Antibody | rhuMab VEGF | Avastin | Anti-Human VEGF | Humanized Antibody | Bevacizumab (Anti-Human VEGF, Humanized Antibody) | Bevacizumab | EC 2.7.10.1 antibody | FLT 1 antibody | FLT antibody | Flt-1 antibody | FLT1 antibody | Fms |
| Specifications & Purity | Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, Animal Free, ≥95%(SDS-PAGE&SEC-HPLC), See COA |
| Host species | Human |
| Specificity | VEGFA |
| Application | ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) |
| Conjugation | Unconjugated |
| Grade | Animal Free, Azide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated |
| Action Type | INHIBITOR |
| Mechanism of action | INHIBITOR of Vascular endothelial growth factor A inhibitor |
| Product Description |
Bevacizumab is a humanized anti-VEGF monoclonal antibody which binds to and neutralizes all human VEGF-A isoforms and bioactive proteolytic fragments. |
| Antibody Type | Primary antibody |
|---|---|
| Clonality | Recombinant |
| Isotype | Human IgG1 |
| Light Chain Type | kappa |
| SDS-PAGE | 26.5 kDa (Light Chain) & 51.7 kDa (Heavy Chain), under reducing conditions; 173.3 kDa, under non-reducing conditions. |
| Purification Method | Protein A purified |
| Purity | >95% |
| Source | CHO supernatant |
| Shape | Liquid |
| Concentration | See COA |
| Storage Temp | Store at -80°C,Avoid repeated freezing and thawing |
| Shipped In | Ice chest + Ice pads |
| Stability And Storage | Store at -80℃ for 24 months. Upon receipt, it is recommended to aliquot. Avoid freeze/thaw cycle. |
| CAS | 216974-75-3 |
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Bevacizumab (anti-VEGF) (B411998) - ELISA
Immobilized Recombinant Human VEGF Protein (rp155965) at 1 μg/mL can bind Bevacizumab (anti-VEGF) (B411998) with the EC50 of 4.16 ng/mL.
Bevacizumab (anti-VEGF) (B411998) - SEC
The purity of Bevacizumab (anti-VEGF) (B411998) is more than 95% verified by HPLC.
Find and download the COA for your product by matching the lot number on the packaging.
| Lot Number | Certificate Type | Date | Item |
|---|---|---|---|
| Certificate of Analysis | Mar 01, 2024 | B411998 | |
| Certificate of Analysis | Aug 21, 2023 | B411998 | |
| Certificate of Analysis | Aug 21, 2023 | B411998 |
Starting at $59.90
Starting at $66.90
Starting at $109.90
Starting at $66.90
Starting at $66.90
| 1. Wenjuan Huang, Liwen Wang, Ruhui Yang, Ronggui Hu, Qinxiang Zheng, Xingjie Zan. (2022) Combined delivery of small molecule and protein drugs as synergistic therapeutics for treating corneal neovascularization by a one-pot coassembly strategy. Materials Today Bio, 17 (100456). |